Logo image of SLNO

SOLENO THERAPEUTICS INC (SLNO) Stock Fundamental Analysis

NASDAQ:SLNO - Nasdaq - US8342033094 - Common Stock - Currency: USD

46.13  -1.29 (-2.72%)

After market: 46.5 +0.37 (+0.8%)

Fundamental Rating

3

Taking everything into account, SLNO scores 3 out of 10 in our fundamental rating. SLNO was compared to 571 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SLNO as it has an excellent financial health rating, but there are worries on the profitability. SLNO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SLNO had negative earnings in the past year.
In the past year SLNO has reported a negative cash flow from operations.
In the past 5 years SLNO always reported negative net income.
SLNO had a negative operating cash flow in each of the past 5 years.
SLNO Yearly Net Income VS EBIT VS OCF VS FCFSLNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

SLNO has a Return On Assets (-44.21%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -49.55%, SLNO is in the better half of the industry, outperforming 65.78% of the companies in the same industry.
Industry RankSector Rank
ROA -44.21%
ROE -49.55%
ROIC N/A
ROA(3y)-66.45%
ROA(5y)-63.58%
ROE(3y)-143.69%
ROE(5y)-138.19%
ROIC(3y)N/A
ROIC(5y)N/A
SLNO Yearly ROA, ROE, ROICSLNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLNO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLNO Yearly Profit, Operating, Gross MarginsSLNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K -2.5K

More info and screens

8

2. Health

2.1 Basic Checks

SLNO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SLNO has been increased compared to 5 years ago.
There is no outstanding debt for SLNO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SLNO Yearly Shares OutstandingSLNO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
SLNO Yearly Total Debt VS Total AssetsSLNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

An Altman-Z score of 34.82 indicates that SLNO is not in any danger for bankruptcy at the moment.
The Altman-Z score of SLNO (34.82) is better than 96.79% of its industry peers.
There is no outstanding debt for SLNO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 34.82
ROIC/WACCN/A
WACCN/A
SLNO Yearly LT Debt VS Equity VS FCFSLNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

SLNO has a Current Ratio of 17.26. This indicates that SLNO is financially healthy and has no problem in meeting its short term obligations.
SLNO has a better Current ratio (17.26) than 91.98% of its industry peers.
A Quick Ratio of 17.26 indicates that SLNO has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 17.26, SLNO belongs to the best of the industry, outperforming 91.98% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.26
Quick Ratio 17.26
SLNO Yearly Current Assets VS Current LiabilitesSLNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for SLNO have decreased by -3.11% in the last year.
EPS 1Y (TTM)-3.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-92.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 16.83% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-45.04%
EPS Next 2Y2.46%
EPS Next 3Y16.83%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLNO Yearly Revenue VS EstimatesSLNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
SLNO Yearly EPS VS EstimatesSLNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SLNO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SLNO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLNO Price Earnings VS Forward Price EarningsSLNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLNO Per share dataSLNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as SLNO's earnings are expected to grow with 16.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.46%
EPS Next 3Y16.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SLNO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOLENO THERAPEUTICS INC

NASDAQ:SLNO (2/21/2025, 8:00:02 PM)

After market: 46.5 +0.37 (+0.8%)

46.13

-1.29 (-2.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)03-04 2025-03-04/amc
Inst Owners114.62%
Inst Owner Change-81.6%
Ins Owners2.48%
Ins Owner Change-3.44%
Market Cap1.99B
Analysts86.15
Price Target75.74 (64.19%)
Short Float %11.14%
Short Ratio8.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-89.94%
Min EPS beat(2)-186.49%
Max EPS beat(2)6.6%
EPS beat(4)1
Avg EPS beat(4)-63.82%
Min EPS beat(4)-186.49%
Max EPS beat(4)6.6%
EPS beat(8)3
Avg EPS beat(8)-37.87%
EPS beat(12)6
Avg EPS beat(12)-19.15%
EPS beat(16)8
Avg EPS beat(16)-15.27%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-17.69%
EPS NQ rev (3m)-17.69%
EPS NY rev (1m)-2.05%
EPS NY rev (3m)-50.77%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.51
P/tB 7.73
EV/EBITDA N/A
EPS(TTM)-3.32
EYN/A
EPS(NY)-2.82
Fwd EYN/A
FCF(TTM)-1.2
FCFYN/A
OCF(TTM)-1.19
OCFYN/A
SpS0
BVpS6.14
TBVpS5.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.21%
ROE -49.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.45%
ROA(5y)-63.58%
ROE(3y)-143.69%
ROE(5y)-138.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.65%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.26
Quick Ratio 17.26
Altman-Z 34.82
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)0.51%
Cap/Depr(5y)0.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-92.63%
EPS Next Y-45.04%
EPS Next 2Y2.46%
EPS Next 3Y16.83%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-330.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-129.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-128.51%
OCF growth 3YN/A
OCF growth 5YN/A